Wentai Pang

Dr. Wentai Pang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YLYaoyuan Liu
Yaoyuan Liu
PNPuyu Niu
Puyu Niu
JYJingxian Yan
Jingxian Yan
HJHongchang Ji
Hongchang Ji
ZWZhaoqi Wang
Zhaoqi Wang
WPWentai Pang
Wentai Pang

13 June 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZGZixuan Gao
Zixuan Gao
YLYaoyuan Liu
Yaoyuan Liu
WLWeiwen Liao
Weiwen Liao
WSWenting Song
Wenting Song
XZXinyi Zhang
Xinyi Zhang
WPWentai Pang
Wentai Pang
Introduction: To evaluate the efficacy and safety of Rhodiola crenulata extract (RCE) for the treatment of patients with acute high altitude disease (AHAD).Methods: This study systematically retrieved randomized controlled trials (RCTs) published prior to September 2024 from eight distinct databases. It included AHAD patients, with the control group receiving either conventional western medicine (WM) or placebo, and the experimental group receiving RCE alone or in conjunction with WM. The primary outcomes were arterial oxygen saturation (SaO2) and arterial partial pressure of oxygen (PaO2). The secondary outcomes were total clinical efficacy, systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Adverse events incidence was analyzed to assess safety. The meta-analysis was performed with Review Manager 5.4, and the evidence’s certainty was assessed using the GRADE approach.Results: This study included 19 eligible RCTs with 1,690 participants. In improving SaO2, PaO2 and total clinical efficacy, no significant differences were found between RCE and WM, but RCE was more effective than placebo. RCE showed no significant effect in reducing SBP, DBP and HR. Regarding safety, the experimental group demonstrated superior performance compared to the control group.Conclusion: RCE may enhance blood oxygen levels and mitigate clinical symptoms in the treatment of AHAD with favorable safety. Nonetheless, it is imperative to undertake further rigorous RCTs to validate these findings.Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/myprospero, identifier CRD42024593081.

19 January 2023 in Acupuncture and Herbal Medicine
Verified
Journal Article
Open access
TLTao Li
Tao Li
MZMin Zhao
Min Zhao
MZMingjun Zhu
Mingjun Zhu
SZShixi Zhang
Shixi Zhang
JHJiarong He
Jiarong He
WPWentai Pang
Wentai Pang
Objective: To evaluate the efficacy and safety of Xuanfei Baidu decoction for treating coronavirus disease 2019 (COVID-19). Methods: Patients with COVID-19 were enrolled, and eligible patients were randomly allocated to three groups: group A (Xuanfei Baidu decoction combined with conventional treatment), group B (Ganlu Xiaodu decoction combined with conventional treatment), and group C (conventional treatment only). The duration of treatment was 14 days. The primary outcomes were the duration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid testing from positive to negative and hospitalization days. The secondary outcome was the rate of symptom resolution. The safety outcome was drug-related adverse events. Results: In total, 103 patients with ordinary-type COVID-19 were included and randomly allocated to groups A (34 cases), B (35 cases), and C (34 cases). Duration for SARS-CoV-2 nucleic acid testing from positive to negative was shortest in group A [(9.88 ± 3.62) days], followed by groups C [(11.20 ± 2.93) days] and B [(12.69 ± 4.11) days]; differences between the three groups were statistically significant (P = 0.010). The number of hospitalization days was the least in group A [(14.00 ± 6.55) days], followed by groups B [(15.40 ± 4.02) days] and C [(16.38 ± 5.73) days], and differences between groups were statistically significant (P = 0.019). There was no statistically significant difference in the rate of symptom resolution between groups (P > 0.05). No deaths or serious adverse events occurred in either of the groups. Conclusion: Considering the treatment of ordinary-type COVID-19, Xuanfei Baidu decoction can shorten the duration from a positive to negative SARS-CoV-2 nucleic acid test, as well as the duration of hospitalization. Moreover, there were no Xuanfei Baidu decoction-induced adverse reactions. Graphical http://links.lww.com/AHM/A44.

5 June 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YLYaoyuan Liu
Yaoyuan Liu
PNPuyu Niu
Puyu Niu
HJHongchang Ji
Hongchang Ji
ZCZhe Chen
Zhe Chen
JZJingbo Zhai
Jingbo Zhai
WPWentai Pang
Wentai Pang
Background: As a bioactive metabolite preparation widely used in acute ischemic stroke (AIS), the efficacy and safety of Panax notoginseng saponins injections (PNSI) in patients with AIS after intravenous thrombolysis remain to be evaluated.Methods: This study included randomized controlled trials published before 26 April 2024 in 8 databases. AIS patients who received intravenous thrombolysis were included. The control group receiving conventional treatment and the treatment group receiving additional PNSI. Primary outcomes were selected as mortality, disability, and adverse events. Secondary outcomes were selected as all-cause mortality, improvement of neurological deficit, quality of life, and cerebral injury indicators. The revised Cochrane Risk of Bias tool was used to assess risk of bias. Risk ratio (RR) and mean differences (MD) were calculated for binary variables and continuous variables, respectively, based on a 95% confidence interval (CI).Results: A total of 20 trials involving 1,856 participants were included. None of them reported mortality or disability. There was no significant difference in the adverse events [RR: 1.04; 95% CI: 0.60 to 1.81] and hemorrhagic transformation [RR: 0.99; 95% CI: 0.36 to 2.70] between the two groups. Compared to the control group, the treatment group had a better effect in neurological improvement assessed by National Institutes of Health Stroke Scale [MD: −2.91; 95% CI: −4.76 to −1.06], a better effect in activities of daily living changes in Barthel Index [MD: 9.37; 95% CI: 1.86 to 16.88], and a lower serum neuron-specific enolase level [MD: −2.08; 95% CI: −2.67 to −1.49].Conclusion: For AIS patients undergoing intravenous thrombolysis, the use of PNSI improved neurological deficits and enhanced activity of daily living in the short term without increasing the occurrence rate of adverse events. However, due to the moderate to very low certainty of evidence, it is advisable to conduct high-quality clinical trials to validate the findings of this study.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=466851, Identifier CRD42023466851

19 May 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
WSWenting Song
Wenting Song
YLYaoyuan Liu
Yaoyuan Liu
CKChaofan Kang
Chaofan Kang
YZYazi Zhang
Yazi Zhang
XYXing Yan
Xing Yan
WPWentai Pang
Wentai Pang
Objective: To evaluate the efficacy and safety of Shuxuening injection (SXNI) in the treatment of patients with intracerebral hemorrhage (ICH).Methods: This study included randomized controlled trials published before 1 June 2024 in eight databases. Patients with ICH were included, with the control group receiving conventional treatment (CT) and the treatment group receiving additional SXNI on this basis. The primary outcome was neurological impairment score. The secondary outcomes were overall efficacy, cerebral hematoma volume, cerebral edema volume, activities of daily living (ADL) score, erythrocyte sedimentation rate (ESR), hematocrit (HCT), hypersensitive C-reactive protein (hs-CRP), low cut whole blood viscosity, high cut whole blood viscosity and adverse events (AE). The methodological quality of the included studies was assessed using the revised Cochrane Risk of Bias tool (ROB 2.0). For binary variables, risk ratios (RR) were calculated, while for continuous variables, mean differences (MD) or standardized mean differences (SMD) were calculated, based on 95% confidence intervals (CI).Results: A total of 29 trials involving 3,012 participants were included. Compared with the control group, the treatment group demonstrated better performance in reducing neurological impairment score [SMD = −0.99, 95% CI −1.24, −0.73], improving overall efficacy [RR = 1.22, 95% CI 1.14, 1.30] and ADL score [SMD = 2.01, 95%CI 1.55, 2.46], as well as decreasing the cerebral hematoma volume [MD = −6.98, 95% CI −8.76, −5.20] and cerebral edema volume [MD = −3.67, 95%CI -5.27, −2.06], with statistically significant differences observed. Meanwhile, the incidence of AE in the treatment group was lower than that in the control group, with a statistically significant difference [RR = 0.63, 95%CI 0.41, 0.96].Conclusion: This study indicates that the combined use of SXNI and CT may be beneficial for the treatment of patients with cerebral hemorrhage compared to the use of CT alone. However, due to the moderate to very low certainty of evidence, it is advisable to conduct highquality clinical trials to validate the findings of this study.

24 September 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
XZXiaoyue Zhao
Xiaoyue Zhao
YLYaoyuan Liu
Yaoyuan Liu
LYLiying Yang
Liying Yang
ZCZeqi Chen
Zeqi Chen
WZWenjun Zhang
Wenjun Zhang
WPWentai Pang
Wentai Pang
Objective: To systematically evaluate the efficacy and safety of Compound Danshen Dripping Pills (CDP) in the treatment of stable angina pectoris (SAP) and provide updated evidence regarding its clinical application. Methods: A comprehensive literature search was conducted in eight electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang Data, VIP, and SinoMed, from inception to 31 May 2026. Randomized controlled trials (RCTs) comparing CDP plus conventional therapy (CT) with CT alone or CT plus nitrates in patients with SAP were included. Primary outcomes included angina efficacy, electrocardiogram (ECG) efficacy, angina frequency, angina duration, and nitroglycerin consumption. Secondary outcomes included lipid profile, left ventricular ejection fraction (LVEF), and fibrinogen (FIB), while adverse events were assessed as safety outcomes. Meta-analysis was performed using Review Manager 5.4 and Stata 18.0, and the certainty of evidence was evaluated using the GRADE framework. Results: A total of 93 RCTs involving 10,208 participants were included. Compared with CT alone, adjunctive CDP was associated with improvements in angina efficacy (RR = 1.26, 95% CI: 1.19–1.33), ECG efficacy (RR = 1.34, 95% CI: 1.19–1.51), reduced angina frequency (SMD = −1.32, 95% CI: −1.79 to −0.84) and duration (SMD = −2.51, 95% CI: -3.58 to −1.45), and increased LVEF (SMD = 1.30, 95% CI: 0.24–2.37). Compared with nitrates plus CT, CDP plus CT also demonstrated comparable or superior improvements in angina efficacy (RR = 1.11, 95% CI: 1.08–1.15), ECG efficacy (RR = 1.35, 95% CI: 1.30–1.40), angina frequency, lipid profile, FIB, and several functional outcomes. CDP was generally well tolerated, with no increased risk of adverse events compared with CT alone and a lower incidence than nitrate-based therapy. However, the certainty of evidence ranged from moderate to very low, mainly due to methodological limitations and inconsistency among included studies. Conclusion: Current evidence suggests that CDP-containing regimens may improve symptomatic and functional outcomes in patients with SAP compared with CT alone or nitrate-containing regimens; however, the certainty of evidence remains limited, and well-designed RCTs are needed to confirm these findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/myprospero , Identifier CRD420261416404.